Dimerix hits milestone in fight with kidney disease
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Dimerix (ASX:DMX), an Australian biotechnology company currently undergoing clinical-stage trials of its flagship drug DMX-200, has announced a significant milestone in reaching 10 patients.
DMX-200 combines irbesartan and propagermanium in the treatment of chronic kidney disease (CKD) and has been shown to improve the outcome of CKD by reducing proteinuria by more than 50% in animal tests.
DXB announced it is on track to report interim data from its DMX-200 Phase II trial in patients with CKD after accumulating 11 patients.
Dimerix’s proprietary screening assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), was used to identify DMX-200 and formed the basis of an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease. The assay enables the identification of pairs of receptors that interact when ligands, small molecule drugs, peptides or antibodies, and then bind to them.
In addition to its own therapeutic programs, DXB also earns revenue by providing this technology to global pharmaceutical firms.
DMX-200 combines two existing drugs, a chemokine receptor CCR2 blocker (propagermanium) used for its anti-inflammatory properties, and an angiotensin II type I receptor blocker (irbesartan) which is registered in the USA for hypertension and treatment of diabetic nephropathy in certain patients.
Dimerix Executive Chairman Dr. James Williams said, “The milestone of dosing 10 patients is an important one, as it should enable interim information to be elucidated under the trial. It confirms we are meeting the recruitment targets and timelines previously communicated to the market.”
Dimerix Executive Chairman Dr James Williams
Finfeed interviewed Mr. Williams in late March 2016, discussing DXB’s kidney disease research, its recent progress as well as future plans.
Dimerix is conducting its clinical trial in two parts.
Part A trials dose escalation trial in up to 30 patients. All patients are provided with stable irbesartan therapy and orally treated with propagermanium three times per day. The plan is for each patient to commence on 30mg PPG/day with the dose incrementally raised every 28 days up to a maximum of 240mg PPG/day, or until proteinuria is absent or reduced.
Reducing proteinuria reduces the risk of CKD progression and its consequences of progressive loss of renal function leading to renal failure, and the development and progression of cardiovascular disease.
Part B constitutes an expansion study for DXB in which up to 30 more patients are enrolled with the best dose identified from Part A. DXB expects to review the design of Part B in consultation with the United State Food and Drug Administration (FDA) before embarking on Part B. Dimerix aims to provide an interim data analysis based on 10-15 patients in the trial before the end of the third quarter of 2016.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
